# Rui Jing

> Rui Jing Jiang is the Founder and CEO of Avisi Technologies, a Redwood City-based clinical-stage medical device company developing VisiPlate, the world's thinnest freestanding ophthalmic implant for treating glaucoma. Built on University of Pennsylvania nanotechnology, VisiPlate is a multichannel aqueous shunt composed of alumina and Parylene-C that is 20 times thinner than a human hair. Rui Jing co-founded the company in 2017 as a junior at Penn's Wharton School, won the $100,000 President's Innovation Prize in 2018, secured FDA Investigational Device Exemption approval in October 2025 for the US SAPPHIRE trial, and closed a $10.7M Series A in February 2026 to advance pivotal clinical development.

- **Role:** Founder and CEO at Avisi Technologies
- **Organizations:** Avisi Technologies, University of Pennsylvania (Wharton School), Allergan, Sanofi Genzyme, JP Morgan, UCSF Rosenman Institute, MedTech Innovator Accelerator, Johnson & Johnson JLABS, AdvaMed, Nano Entrepreneurship Network (U.S. National Nanotechnology Initiative)
- **Nationality:** American
- **Education:** B.S. Economics (Finance and Strategic Management), cum laude, University of Pennsylvania - Wharton School, Summer Institute participant, University of Pennsylvania - Jerome Fisher Program in Management & Technology (M&TSI)
- **Known for:** Won Penn President's Innovation Prize ($100,000) in 2018 for Avisi Technologies, Secured FDA Investigational Device Exemption (IDE) approval for SAPPHIRE trial in October 2025, VisiPlate achieved 42.6% IOP reduction and 46.7% medication-free rate at 12 months in VITA trial

## Career timeline

- **2013** — Participated in Penn's M&TSI summer program; met co-founder Brandon Kao
- **2014-2018** — Attended Wharton School, University of Pennsylvania; graduated cum laude
- **2016** — Team begins developing VisiPlate concept under mentorship at Penn
- **2017** — Founded Avisi Technologies through Penn Y-Prize program; won Y-Prize competition
- **2018** — Won Penn President's Innovation Prize ($100,000 + stipend); began full-time operations at Pennovation Center
- **2018** — Worked at Allergan in corporate development, strategic marketing, and product management
- **2018-2019** — Completed rotations at Sanofi Genzyme and JP Morgan
- **2019** — Featured in Wharton Magazine; received NSF SBIR Phase II grant ($1M)
- **2020** — Named UCSF Rosenman Innovator; featured as Healthtech Leader of the Month; named Philadelphia Inno Under 25
- **2021** — Became Venture Lab Entrepreneur in Residence (VIP EIR) at Penn
- **2022** — Named Fierce Life Sciences Innovation Awards finalist; Theia interview on FDA regulatory pathways
- **2023** — Closed seed round ($4.06M) and initial Series A ($4M) led by Accanto Partners; presented at LSI USA '23
- **2024** — Keynote presentation at LSI USA '24 Emerging Medtech Summit
- **2025-04** — Announced positive 6-month VITA trial data at American Glaucoma Society meeting
- **2025-10** — FDA grants Investigational Device Exemption (IDE) approval for SAPPHIRE US clinical trial
- **2025-11** — Presented positive 12-month VITA trial data at AAO Annual Meeting
- **2025-12** — First patient implanted with VisiPlate in SAPPHIRE trial
- **2026-02** — Closed $10.7M Series A round led by MedVenture Partners

## Achievements

- Won Penn President's Innovation Prize ($100,000) in 2018 for Avisi Technologies
- Secured FDA Investigational Device Exemption (IDE) approval for SAPPHIRE trial in October 2025
- VisiPlate achieved 42.6% IOP reduction and 46.7% medication-free rate at 12 months in VITA trial
- Closed $10.7M Series A in February 2026; total funding of ~$25.26M
- Named Philadelphia Inno Under 25 by Philadelphia Business Journal
- UCSF Rosenman Innovator and Healthtech Leader of the Month
- 2019 SXSW Innovation Awards finalist in Health, Med, and Biotech
- 2022 Fierce Life Sciences Innovation Awards finalist in Medical Device Innovation
- NSF SBIR Phase II grant recipient ($1M)
- MedTech Innovator Accelerator participant
- Johnson & Johnson JLABS member company
- Featured in Wharton Magazine Watchlist
- Named among 'Ten most promising Philadelphia tech companies of the decade' by Technical.ly
- Graduated cum laude from Wharton School, University of Pennsylvania
- Speaker at LSI USA '23, '24, and '25 Emerging Medtech Summits

## Latest updates

- **2026-02** — Avisi Technologies closed $10.7M Series A round led by MedVenture Partners to fund SAPPHIRE pivotal trial
- **2025-12** — First patient implanted with VisiPlate in the SAPPHIRE US clinical trial
- **2025-11** — Presented positive 12-month VITA trial data at AAO 2025: 42.6% IOP reduction, 46.7% medication-free rate
- **2025-10** — FDA granted Investigational Device Exemption (IDE) approval for SAPPHIRE trial
- **2025-04** — Presented positive 6-month interim VITA trial data at American Glaucoma Society annual meeting
- **2025-04** — Participated in LSI USA '25 panel: 'Staying Sexy Without GenAI or SaaS'

## Links

- Website: https://avisitech.com
- LinkedIn: http://www.linkedin.com/in/rui-jing-jiang
- Twitter/X: https://twitter.com/rj_sapientia
- Facebook: https://facebook.com/avisitech

---

Profile page: https://yespress.io/rui-jing
Published by YesPress — https://yespress.io
Last updated: 2026-06-06